Cyclic NTCP-targeting peptides and their uses as entry inhibitors
The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.
1. A peptide comprising the amino acid sequence selected from
(SEQ. ID NO: 9)
cyclo[PNPLGFFPDH]
(SEQ. ID NO: 12)
cyclo[NPLGFFPDH]
(SEQ. ID NO: 15)
cyclo[PNPLGFFPDH]
(SEQ. ID NO: 28)
cyclo[PNPLGFLPD]
(SEQ. ID NO: 29)
cyclo[NPLGFLPDH]
(SEQ. ID NO: 30)
cyclo[PNPLGFLPDH]
(SEQ. ID NO: 31)
cyclo[GTNLSVPNPLGFLPDHQLDP],
wherein the peptide carries at least one hydrophobic modification, which an acylation with a C8 to C22 fatty acid and/or addition of hydrophobic moieties, or a pharmaceutically acceptable salt thereof.
2. The peptide of claim 1 , wherein the peptide is cyclized
(a) via thiol oxidation of two cysteines in the peptide,
(b) amide condensation of two amino acid side chains,
(c) via head-to-tail cyclization,
(d) via backbone cyclization,
(e) via thioether formation,
and/or
(f) via hydrogen bond formation and/or bond-forming derivatives of amino acids.
3. The peptide of claim 1 , further comprising an accessory domain, which is part of the cyclic peptide or is acyclic.
4. The peptide of claim 1 , wherein the peptide consists of the amino acid sequence selected from:
HBVpreS9-16
NPLGFFPD
(SEQ ID NO: 6)
HBVpreS8-16
PNPLGFFPD
(SEQ ID NO: 9)
HBVpreS9-1
NPLGFFPDH
(SEQ ID NO: 12)
HBVpreS8-17
PNPLGFFPDH
(SEQ ID NO: 15).
5. The peptide of claim 1 , comprising one or more further moieties,
selected from
drugs and their respective prodrugs;
tags;
labels;
recombinant viruses and derivatives thereof;
carrier or depots for drugs, prodrugs or labels;
immunogenic epitopes;
hormones;
inhibitors; and
toxins.
6. A pharmaceutical composition comprising:
(i) at least one peptide of claim 1 , and
(ii) optionally, a pharmaceutically acceptable carrier and/or excipient.
7. The peptide, according to claim 1 , wherein the peptide consists of the amino acid sequence selected from
(SEQ. ID NO: 9)
Myr-cyclo (myr-cyclo[PNPLGFFPD])
(SEQ. ID NO: 12)
Myr-cyclo (myr-cyclo[NPLGFFPDH])
and
(SEQ. ID NO: 15)
Myr-cyclo (myr-cyclo[PNPLGFFPDH]).
8. The peptide, according to claim 1 , wherein the peptide consists of the amino acid sequence selected from
(SEQ. ID NO: 9)
cyclo[PNPLGFFPD]
(SEQ. ID NO: 12)
cyclo[NPLGFFPDH]
(SEQ. ID NO: 15)
cyclo[PNPLGFFPDH]
(SEQ ID NO. 28)
cyclo[PNPLGFLPD]
(SEQ ID NO. 29)
cyclo[NPLGFLPDH]
(SEQ ID NO. 30)
cyclo[PNPLGFLPDH]
and
(SEQ ID NO. 31)
cyclo[GTNLSVPNPLGFLPDHQLDP].